Back
Fulltext
Journal article

The ultrasound risk stratification systems for thyroid nodule have been evaluated against papillary carcinoma : a meta-analysis

  • Trimboli, Pierpaolo Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland - Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
  • Castellana, Marco National Institute of Gastroenterology “Saverio de Bellis”, Research Hospital, Castellana Grotte, Bari, Italy
  • Piccardo, Arnoldo Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy
  • Romanelli, Francesco Department of Experimental Medicine, “Sapienza” University of Rome, Italy
  • Grani, Giorgio Department of Translational and Precision Medicine, Sapienza University of Rome, Italy
  • Giovanella, Luca Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland - Clinic for Nuclear Medicine, University Hospital and University of Zurich, Switzerland
  • Durante, Cosimo Department of Translational and Precision Medicine, Sapienza University of Rome, Italy
Show more…
    21.09.2020
Published in:
  • Reviews in endocrine and metabolic disorders. - 2021, vol. 22, p. 453–460
Thyroid
Ultrasound
TIRADS
Papillary
Follicular
Medullary
English Thyroid imaging reporting and data systems (TIRADS) are used to stratify the malignancy risk of thyroid nodule by ultrasound (US) examination. We conducted a meta-analysis to evaluate the pooled cancer prevalence and the relative prevalence of papillary, medullary, follicular thyroid cancer (PTC, MTC, and FTC) and other malignancies among nodules included in studies evaluating their performance. Four databases were searched until February 2020. Original articles with at least 1000 nodules, evaluating the performance of at least one TIRADS among AACE/ACE/AME, ACR-TIRADS, ATA, EU-TIRADS, or K-TIRADS, and reporting data on the histological diagnosis of malignant lesions were included. The number of malignant nodules, PTC, FTC, MTC and other malignancies in each study was extracted. For statistical pooling of data, a random-effects model was used. Nine studies were included, evaluating 19,494 thyroid nodules. The overall prevalence of malignancy was 34% (95%CI 21 to 49). Among 6162 histologically proven malignancies, the prevalence of PTC, FTC, MTC and other malignancies was 95%, 2%, 1%, and 1%, respectively. A high heterogeneity was found for all the outcomes. A limited number of studies generally conducted using a retrospective design was found, with possible selection bias. Acknowledging this limitation, TIRADSs should be regarded as accurate tools to diagnose PTC only. Proposed patterns and/or cut-offs should be revised and other strategies considered to improve their performance in the assessment of FTC, MTC and other malignancies.
Language
  • English
Classification
Pathology, clinical medicine
License
CC BY
Open access status
hybrid
Identifiers
Persistent URL
https://n2t.net/ark:/12658/srd1319250
Statistics
Document views: 102 File downloads:
  • Trimboli_2020_remb_Ultrasoundrisk.pdf: 180